Skip directly to content

Safety Information


Indications and Clinical Use:

  • Management of neuropathic pain associated with:
    • diabetic peripheral neuropathy
    • postherpetic neuralgia
    • spinal cord injury
  • Management of pain associated with fibromyalgia; efficacy for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase

Not indicated in children.

Geriatrics (>65 years of age): dose reduction required due to age-related decreased renal function.

Relevant warnings and precautions:

  • Angioedema, including reports of life-threatening angioedema
    • history of angioedema/related events
    • other drugs associated with angioedema (e.g., ACE inhibitors)
  • Peripheral edema with increased incidence in combination with thiazolidinedione antidiabetic agents
  • Hypersensitivity
  • Renal failure; caution in renal impairment
  • Tumorigenic potential
  • Vision-related adverse events (blurry vision, diplopia)
  • Congestive heart failure
  • Serious skin reactions
  • Lower gastrointestinal tract related events
  • Weight gain
  • Dizziness and somnolence
  • Avoid abrupt or rapid discontinuation
  • Encephalopathy; caution in elderly with age-related compromised renal function and patients with kidney disease or risk factors for renal failure
  • Monitor for suicidal behaviour and ideation
  • Possible effects on male fertility
  • Pregnant patients should enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry
  • Creatinine kinase elevations and rhabdomyolysis
  • Decreased platelets
  • PR interval prolongation

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information (including dose adjustments in renal impairment).

LYRICA ® C.P. Pharmaceuticals International C.V., owner/Pfizer Canada Inc., Licensee